Hong Kong Stock Market Movement | Shishi Pharmaceutical Group(02005) drops over 7%, expected net profit for 2025 to decrease approximately 45% to 60% year-on-year

LootboxPhobia · 2026-02-20T02:26:27+00:00

Shihe Pharmaceutical Group announced that its expected profit for 2025 will decrease by 45%-60%, causing the stock price to drop over 7%. The main reasons are the weakening impact of the epidemic, medical insurance cost control, price pressures, and changes in sales channels.

LootboxPhobia

2026-02-20 02:26:27

Abstract generation in progress

The Zhitong Finance App learned that Shisi Pharmaceutical Group (02005) fell more than 7%, and as of press time, it fell 7.28% to HK$2.8, with a turnover of HK$2.5758 million.

On the news side, Shisi Pharmaceutical Group announced that it expects profit in 2025 to decrease by 45%-60% from HK$1.061 billion in the previous year. Mainly due to the strong market demand for intravenous infusions and other drugs due to the domestic influenza outbreak in the first quarter of 2024, but the terminal sales of drugs declined due to the absence of large-scale epidemics in China and the superimposed medical insurance control fees for the entire year ended December 31, 2025; the expansion of the scope of various forms of volume procurement (including national drug centralized procurement and local alliance centralized procurement) and the intensification of industry competition at home and abroad have brought continuous price pressure; and bromhexine hydrochloride ampoule injection decreased due to the fact that it was no longer sold through the national drug centralized procurement.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes